Affinity: Home blood count monitoring for personalised delivery of cancer therapy

点击翻译按钮获取中文摘要

"50% of people are expected to get cancer at some point in their life. Even with new therapies, many patients will experience unwanted side effects from their treatment that may range from minor psychological issues through to life threatening infections. With cancer patients spending a significant amount of time outside of healthcare facilities, it becomes hard to identify early changes that may lead to such complications. This project shall be the final stage of development for a new home monitoring technology that can reduce unnecessary hospital visits for patients, improve the management of side effects, enhance quality of life and reduce the likelihood of life-threatening adverse events occurring. This platform will operate by allowing recipients of systemic cancer therapy to monitor their blood counts and symptoms within their home whilst sharing that information with their nurses and doctors through a real-time connection that is integrated directly with their care provider. Earlier development work has been undertaken with patients, carers, nurses and clinicians using human centered design processes to ensure that the technology is easy to use and solves genuine problems for people receiving systemic cancer therapy. This project brings together two of the UK's leading hospital trusts, The Royal Marsden NHS Foundation Trust and The Christie NHS Foundation Trust alongside The University of Manchester, Imperial College Health Partners, Entia and iQ Healthtech to ensure this innovation can be rapidly adopted across healthcare."